Global Long-Acting Insulin Analogue Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Long-Acting Insulin Analogue market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Long-Acting Insulin Analogue market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-Acting Insulin Analogue market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-Acting Insulin Analogue
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-Acting Insulin Analogue market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings, Tonghua Dongbao Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-Acting Insulin Analogue market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-Acting Insulin Analogue product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-Acting Insulin Analogue, with price, sales quantity, revenue, and global market share of Long-Acting Insulin Analogue from 2020 to 2025.
Chapter 3, the Long-Acting Insulin Analogue competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-Acting Insulin Analogue breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Long-Acting Insulin Analogue market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-Acting Insulin Analogue.
Chapter 14 and 15, to describe Long-Acting Insulin Analogue sales channel, distributors, customers, research findings and conclusion.
This report is a detailed and comprehensive analysis for global Long-Acting Insulin Analogue market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-Acting Insulin Analogue market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Long-Acting Insulin Analogue market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-Acting Insulin Analogue
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-Acting Insulin Analogue market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings, Tonghua Dongbao Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-Acting Insulin Analogue market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Insulin Glargine
- Insulin Detemir
- Insulin Degludec
- Type 2 Diabetes
- Type 1 Diabetes
- Gestational Diabetes
- Other Diabetes
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Gan and Lee Pharmaceuticals
- The United Laboratories International Holdings
- Tonghua Dongbao Pharmaceutical
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-Acting Insulin Analogue product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-Acting Insulin Analogue, with price, sales quantity, revenue, and global market share of Long-Acting Insulin Analogue from 2020 to 2025.
Chapter 3, the Long-Acting Insulin Analogue competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-Acting Insulin Analogue breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Long-Acting Insulin Analogue market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-Acting Insulin Analogue.
Chapter 14 and 15, to describe Long-Acting Insulin Analogue sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Long-Acting Insulin Analogue Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Insulin Glargine
1.3.3 Insulin Detemir
1.3.4 Insulin Degludec
1.4 Market Analysis by Application
1.4.1 Overview: Global Long-Acting Insulin Analogue Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Type 2 Diabetes
1.4.3 Type 1 Diabetes
1.4.4 Gestational Diabetes
1.4.5 Other Diabetes
1.5 Global Long-Acting Insulin Analogue Market Size & Forecast
1.5.1 Global Long-Acting Insulin Analogue Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Long-Acting Insulin Analogue Sales Quantity (2020-2031)
1.5.3 Global Long-Acting Insulin Analogue Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Long-Acting Insulin Analogue Product and Services
2.1.4 Novo Nordisk Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Long-Acting Insulin Analogue Product and Services
2.2.4 Sanofi Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Sanofi Recent Developments/Updates
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Long-Acting Insulin Analogue Product and Services
2.3.4 Eli Lilly and Company Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Eli Lilly and Company Recent Developments/Updates
2.4 Gan and Lee Pharmaceuticals
2.4.1 Gan and Lee Pharmaceuticals Details
2.4.2 Gan and Lee Pharmaceuticals Major Business
2.4.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product and Services
2.4.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Gan and Lee Pharmaceuticals Recent Developments/Updates
2.5 The United Laboratories International Holdings
2.5.1 The United Laboratories International Holdings Details
2.5.2 The United Laboratories International Holdings Major Business
2.5.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Product and Services
2.5.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 The United Laboratories International Holdings Recent Developments/Updates
2.6 Tonghua Dongbao Pharmaceutical
2.6.1 Tonghua Dongbao Pharmaceutical Details
2.6.2 Tonghua Dongbao Pharmaceutical Major Business
2.6.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product and Services
2.6.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: LONG-ACTING INSULIN ANALOGUE BY MANUFACTURER
3.1 Global Long-Acting Insulin Analogue Sales Quantity by Manufacturer (2020-2025)
3.2 Global Long-Acting Insulin Analogue Revenue by Manufacturer (2020-2025)
3.3 Global Long-Acting Insulin Analogue Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Long-Acting Insulin Analogue by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Long-Acting Insulin Analogue Manufacturer Market Share in 2024
3.4.3 Top 6 Long-Acting Insulin Analogue Manufacturer Market Share in 2024
3.5 Long-Acting Insulin Analogue Market: Overall Company Footprint Analysis
3.5.1 Long-Acting Insulin Analogue Market: Region Footprint
3.5.2 Long-Acting Insulin Analogue Market: Company Product Type Footprint
3.5.3 Long-Acting Insulin Analogue Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Long-Acting Insulin Analogue Market Size by Region
4.1.1 Global Long-Acting Insulin Analogue Sales Quantity by Region (2020-2031)
4.1.2 Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2031)
4.1.3 Global Long-Acting Insulin Analogue Average Price by Region (2020-2031)
4.2 North America Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.3 Europe Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.4 Asia-Pacific Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.5 South America Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.6 Middle East & Africa Long-Acting Insulin Analogue Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
5.2 Global Long-Acting Insulin Analogue Consumption Value by Type (2020-2031)
5.3 Global Long-Acting Insulin Analogue Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
6.2 Global Long-Acting Insulin Analogue Consumption Value by Application (2020-2031)
6.3 Global Long-Acting Insulin Analogue Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
7.2 North America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
7.3 North America Long-Acting Insulin Analogue Market Size by Country
7.3.1 North America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
7.3.2 North America Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
8.2 Europe Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
8.3 Europe Long-Acting Insulin Analogue Market Size by Country
8.3.1 Europe Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
8.3.2 Europe Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Long-Acting Insulin Analogue Market Size by Region
9.3.1 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
10.2 South America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
10.3 South America Long-Acting Insulin Analogue Market Size by Country
10.3.1 South America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
10.3.2 South America Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Long-Acting Insulin Analogue Market Size by Country
11.3.1 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 Long-Acting Insulin Analogue Market Drivers
12.2 Long-Acting Insulin Analogue Market Restraints
12.3 Long-Acting Insulin Analogue Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Long-Acting Insulin Analogue and Key Manufacturers
13.2 Manufacturing Costs Percentage of Long-Acting Insulin Analogue
13.3 Long-Acting Insulin Analogue Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Long-Acting Insulin Analogue Typical Distributors
14.3 Long-Acting Insulin Analogue Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Long-Acting Insulin Analogue Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Insulin Glargine
1.3.3 Insulin Detemir
1.3.4 Insulin Degludec
1.4 Market Analysis by Application
1.4.1 Overview: Global Long-Acting Insulin Analogue Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Type 2 Diabetes
1.4.3 Type 1 Diabetes
1.4.4 Gestational Diabetes
1.4.5 Other Diabetes
1.5 Global Long-Acting Insulin Analogue Market Size & Forecast
1.5.1 Global Long-Acting Insulin Analogue Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Long-Acting Insulin Analogue Sales Quantity (2020-2031)
1.5.3 Global Long-Acting Insulin Analogue Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Long-Acting Insulin Analogue Product and Services
2.1.4 Novo Nordisk Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Long-Acting Insulin Analogue Product and Services
2.2.4 Sanofi Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Sanofi Recent Developments/Updates
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Long-Acting Insulin Analogue Product and Services
2.3.4 Eli Lilly and Company Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Eli Lilly and Company Recent Developments/Updates
2.4 Gan and Lee Pharmaceuticals
2.4.1 Gan and Lee Pharmaceuticals Details
2.4.2 Gan and Lee Pharmaceuticals Major Business
2.4.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product and Services
2.4.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Gan and Lee Pharmaceuticals Recent Developments/Updates
2.5 The United Laboratories International Holdings
2.5.1 The United Laboratories International Holdings Details
2.5.2 The United Laboratories International Holdings Major Business
2.5.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Product and Services
2.5.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 The United Laboratories International Holdings Recent Developments/Updates
2.6 Tonghua Dongbao Pharmaceutical
2.6.1 Tonghua Dongbao Pharmaceutical Details
2.6.2 Tonghua Dongbao Pharmaceutical Major Business
2.6.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product and Services
2.6.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: LONG-ACTING INSULIN ANALOGUE BY MANUFACTURER
3.1 Global Long-Acting Insulin Analogue Sales Quantity by Manufacturer (2020-2025)
3.2 Global Long-Acting Insulin Analogue Revenue by Manufacturer (2020-2025)
3.3 Global Long-Acting Insulin Analogue Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Long-Acting Insulin Analogue by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Long-Acting Insulin Analogue Manufacturer Market Share in 2024
3.4.3 Top 6 Long-Acting Insulin Analogue Manufacturer Market Share in 2024
3.5 Long-Acting Insulin Analogue Market: Overall Company Footprint Analysis
3.5.1 Long-Acting Insulin Analogue Market: Region Footprint
3.5.2 Long-Acting Insulin Analogue Market: Company Product Type Footprint
3.5.3 Long-Acting Insulin Analogue Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Long-Acting Insulin Analogue Market Size by Region
4.1.1 Global Long-Acting Insulin Analogue Sales Quantity by Region (2020-2031)
4.1.2 Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2031)
4.1.3 Global Long-Acting Insulin Analogue Average Price by Region (2020-2031)
4.2 North America Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.3 Europe Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.4 Asia-Pacific Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.5 South America Long-Acting Insulin Analogue Consumption Value (2020-2031)
4.6 Middle East & Africa Long-Acting Insulin Analogue Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
5.2 Global Long-Acting Insulin Analogue Consumption Value by Type (2020-2031)
5.3 Global Long-Acting Insulin Analogue Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
6.2 Global Long-Acting Insulin Analogue Consumption Value by Application (2020-2031)
6.3 Global Long-Acting Insulin Analogue Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
7.2 North America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
7.3 North America Long-Acting Insulin Analogue Market Size by Country
7.3.1 North America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
7.3.2 North America Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
8.2 Europe Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
8.3 Europe Long-Acting Insulin Analogue Market Size by Country
8.3.1 Europe Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
8.3.2 Europe Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Long-Acting Insulin Analogue Market Size by Region
9.3.1 Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
10.2 South America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
10.3 South America Long-Acting Insulin Analogue Market Size by Country
10.3.1 South America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
10.3.2 South America Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Long-Acting Insulin Analogue Market Size by Country
11.3.1 Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 Long-Acting Insulin Analogue Market Drivers
12.2 Long-Acting Insulin Analogue Market Restraints
12.3 Long-Acting Insulin Analogue Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Long-Acting Insulin Analogue and Key Manufacturers
13.2 Manufacturing Costs Percentage of Long-Acting Insulin Analogue
13.3 Long-Acting Insulin Analogue Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Long-Acting Insulin Analogue Typical Distributors
14.3 Long-Acting Insulin Analogue Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF FIGURES
Table 1. Global Long-Acting Insulin Analogue Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Long-Acting Insulin Analogue Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Long-Acting Insulin Analogue Product and Services
Table 6. Novo Nordisk Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi Major Business
Table 10. Sanofi Long-Acting Insulin Analogue Product and Services
Table 11. Sanofi Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Sanofi Recent Developments/Updates
Table 13. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 14. Eli Lilly and Company Major Business
Table 15. Eli Lilly and Company Long-Acting Insulin Analogue Product and Services
Table 16. Eli Lilly and Company Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. Eli Lilly and Company Recent Developments/Updates
Table 18. Gan and Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Gan and Lee Pharmaceuticals Major Business
Table 20. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product and Services
Table 21. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Gan and Lee Pharmaceuticals Recent Developments/Updates
Table 23. The United Laboratories International Holdings Basic Information, Manufacturing Base and Competitors
Table 24. The United Laboratories International Holdings Major Business
Table 25. The United Laboratories International Holdings Long-Acting Insulin Analogue Product and Services
Table 26. The United Laboratories International Holdings Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. The United Laboratories International Holdings Recent Developments/Updates
Table 28. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 29. Tonghua Dongbao Pharmaceutical Major Business
Table 30. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product and Services
Table 31. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 33. Global Long-Acting Insulin Analogue Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 34. Global Long-Acting Insulin Analogue Revenue by Manufacturer (2020-2025) & (USD Million)
Table 35. Global Long-Acting Insulin Analogue Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 36. Market Position of Manufacturers in Long-Acting Insulin Analogue, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 37. Head Office and Long-Acting Insulin Analogue Production Site of Key Manufacturer
Table 38. Long-Acting Insulin Analogue Market: Company Product Type Footprint
Table 39. Long-Acting Insulin Analogue Market: Company Product Application Footprint
Table 40. Long-Acting Insulin Analogue New Market Entrants and Barriers to Market Entry
Table 41. Long-Acting Insulin Analogue Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 43. Global Long-Acting Insulin Analogue Sales Quantity by Region (2020-2025) & (K Units)
Table 44. Global Long-Acting Insulin Analogue Sales Quantity by Region (2026-2031) & (K Units)
Table 45. Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2025) & (USD Million)
Table 46. Global Long-Acting Insulin Analogue Consumption Value by Region (2026-2031) & (USD Million)
Table 47. Global Long-Acting Insulin Analogue Average Price by Region (2020-2025) & (US$/Unit)
Table 48. Global Long-Acting Insulin Analogue Average Price by Region (2026-2031) & (US$/Unit)
Table 49. Global Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 50. Global Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 51. Global Long-Acting Insulin Analogue Consumption Value by Type (2020-2025) & (USD Million)
Table 52. Global Long-Acting Insulin Analogue Consumption Value by Type (2026-2031) & (USD Million)
Table 53. Global Long-Acting Insulin Analogue Average Price by Type (2020-2025) & (US$/Unit)
Table 54. Global Long-Acting Insulin Analogue Average Price by Type (2026-2031) & (US$/Unit)
Table 55. Global Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 56. Global Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 57. Global Long-Acting Insulin Analogue Consumption Value by Application (2020-2025) & (USD Million)
Table 58. Global Long-Acting Insulin Analogue Consumption Value by Application (2026-2031) & (USD Million)
Table 59. Global Long-Acting Insulin Analogue Average Price by Application (2020-2025) & (US$/Unit)
Table 60. Global Long-Acting Insulin Analogue Average Price by Application (2026-2031) & (US$/Unit)
Table 61. North America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 62. North America Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 63. North America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 64. North America Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 65. North America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 66. North America Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 67. North America Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 68. North America Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 69. Europe Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 70. Europe Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 71. Europe Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 72. Europe Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 73. Europe Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 74. Europe Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 75. Europe Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 76. Europe Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 77. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 78. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 79. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 80. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 81. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2020-2025) & (K Units)
Table 82. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2026-2031) & (K Units)
Table 83. Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2020-2025) & (USD Million)
Table 84. Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2026-2031) & (USD Million)
Table 85. South America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 86. South America Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 87. South America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 88. South America Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 89. South America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 90. South America Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 91. South America Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 92. South America Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 93. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 94. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 95. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 96. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 97. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 98. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 99. Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 100. Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 101. Long-Acting Insulin Analogue Raw Material
Table 102. Key Manufacturers of Long-Acting Insulin Analogue Raw Materials
Table 103. Long-Acting Insulin Analogue Typical Distributors
Table 104. Long-Acting Insulin Analogue Typical Customers
LIST OF FIGURES
Figure 1. Long-Acting Insulin Analogue Picture
Figure 2. Global Long-Acting Insulin Analogue Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Long-Acting Insulin Analogue Revenue Market Share by Type in 2024
Figure 4. Insulin Glargine Examples
Figure 5. Insulin Detemir Examples
Figure 6. Insulin Degludec Examples
Figure 7. Global Long-Acting Insulin Analogue Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Global Long-Acting Insulin Analogue Revenue Market Share by Application in 2024
Figure 9. Type 2 Diabetes Examples
Figure 10. Type 1 Diabetes Examples
Figure 11. Gestational Diabetes Examples
Figure 12. Other Diabetes Examples
Figure 13. Global Long-Acting Insulin Analogue Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Long-Acting Insulin Analogue Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Long-Acting Insulin Analogue Sales Quantity (2020-2031) & (K Units)
Figure 16. Global Long-Acting Insulin Analogue Price (2020-2031) & (US$/Unit)
Figure 17. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Manufacturer in 2024
Figure 18. Global Long-Acting Insulin Analogue Revenue Market Share by Manufacturer in 2024
Figure 19. Producer Shipments of Long-Acting Insulin Analogue by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 20. Top 3 Long-Acting Insulin Analogue Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Long-Acting Insulin Analogue Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Region (2020-2031)
Figure 23. Global Long-Acting Insulin Analogue Consumption Value Market Share by Region (2020-2031)
Figure 24. North America Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 25. Europe Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 27. South America Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 29. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 30. Global Long-Acting Insulin Analogue Consumption Value Market Share by Type (2020-2031)
Figure 31. Global Long-Acting Insulin Analogue Average Price by Type (2020-2031) & (US$/Unit)
Figure 32. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 33. Global Long-Acting Insulin Analogue Revenue Market Share by Application (2020-2031)
Figure 34. Global Long-Acting Insulin Analogue Average Price by Application (2020-2031) & (US$/Unit)
Figure 35. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 36. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 37. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 38. North America Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 39. United States Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 40. Canada Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 41. Mexico Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 42. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 43. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 44. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 45. Europe Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 46. Germany Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 47. France Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 48. United Kingdom Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 49. Russia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 50. Italy Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 52. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Long-Acting Insulin Analogue Consumption Value Market Share by Region (2020-2031)
Figure 55. China Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 56. Japan Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 57. South Korea Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 58. India Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 59. Southeast Asia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 60. Australia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 61. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 62. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 63. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 64. South America Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 65. Brazil Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 66. Argentina Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 70. Middle East & Africa Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 71. Turkey Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 72. Egypt Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 74. South Africa Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 75. Long-Acting Insulin Analogue Market Drivers
Figure 76. Long-Acting Insulin Analogue Market Restraints
Figure 77. Long-Acting Insulin Analogue Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Long-Acting Insulin Analogue in 2024
Figure 80. Manufacturing Process Analysis of Long-Acting Insulin Analogue
Figure 81. Long-Acting Insulin Analogue Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Table 1. Global Long-Acting Insulin Analogue Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Long-Acting Insulin Analogue Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Long-Acting Insulin Analogue Product and Services
Table 6. Novo Nordisk Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi Major Business
Table 10. Sanofi Long-Acting Insulin Analogue Product and Services
Table 11. Sanofi Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Sanofi Recent Developments/Updates
Table 13. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 14. Eli Lilly and Company Major Business
Table 15. Eli Lilly and Company Long-Acting Insulin Analogue Product and Services
Table 16. Eli Lilly and Company Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. Eli Lilly and Company Recent Developments/Updates
Table 18. Gan and Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Gan and Lee Pharmaceuticals Major Business
Table 20. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product and Services
Table 21. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Gan and Lee Pharmaceuticals Recent Developments/Updates
Table 23. The United Laboratories International Holdings Basic Information, Manufacturing Base and Competitors
Table 24. The United Laboratories International Holdings Major Business
Table 25. The United Laboratories International Holdings Long-Acting Insulin Analogue Product and Services
Table 26. The United Laboratories International Holdings Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. The United Laboratories International Holdings Recent Developments/Updates
Table 28. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 29. Tonghua Dongbao Pharmaceutical Major Business
Table 30. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product and Services
Table 31. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 33. Global Long-Acting Insulin Analogue Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 34. Global Long-Acting Insulin Analogue Revenue by Manufacturer (2020-2025) & (USD Million)
Table 35. Global Long-Acting Insulin Analogue Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 36. Market Position of Manufacturers in Long-Acting Insulin Analogue, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 37. Head Office and Long-Acting Insulin Analogue Production Site of Key Manufacturer
Table 38. Long-Acting Insulin Analogue Market: Company Product Type Footprint
Table 39. Long-Acting Insulin Analogue Market: Company Product Application Footprint
Table 40. Long-Acting Insulin Analogue New Market Entrants and Barriers to Market Entry
Table 41. Long-Acting Insulin Analogue Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 43. Global Long-Acting Insulin Analogue Sales Quantity by Region (2020-2025) & (K Units)
Table 44. Global Long-Acting Insulin Analogue Sales Quantity by Region (2026-2031) & (K Units)
Table 45. Global Long-Acting Insulin Analogue Consumption Value by Region (2020-2025) & (USD Million)
Table 46. Global Long-Acting Insulin Analogue Consumption Value by Region (2026-2031) & (USD Million)
Table 47. Global Long-Acting Insulin Analogue Average Price by Region (2020-2025) & (US$/Unit)
Table 48. Global Long-Acting Insulin Analogue Average Price by Region (2026-2031) & (US$/Unit)
Table 49. Global Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 50. Global Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 51. Global Long-Acting Insulin Analogue Consumption Value by Type (2020-2025) & (USD Million)
Table 52. Global Long-Acting Insulin Analogue Consumption Value by Type (2026-2031) & (USD Million)
Table 53. Global Long-Acting Insulin Analogue Average Price by Type (2020-2025) & (US$/Unit)
Table 54. Global Long-Acting Insulin Analogue Average Price by Type (2026-2031) & (US$/Unit)
Table 55. Global Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 56. Global Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 57. Global Long-Acting Insulin Analogue Consumption Value by Application (2020-2025) & (USD Million)
Table 58. Global Long-Acting Insulin Analogue Consumption Value by Application (2026-2031) & (USD Million)
Table 59. Global Long-Acting Insulin Analogue Average Price by Application (2020-2025) & (US$/Unit)
Table 60. Global Long-Acting Insulin Analogue Average Price by Application (2026-2031) & (US$/Unit)
Table 61. North America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 62. North America Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 63. North America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 64. North America Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 65. North America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 66. North America Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 67. North America Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 68. North America Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 69. Europe Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 70. Europe Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 71. Europe Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 72. Europe Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 73. Europe Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 74. Europe Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 75. Europe Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 76. Europe Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 77. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 78. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 79. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 80. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 81. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2020-2025) & (K Units)
Table 82. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity by Region (2026-2031) & (K Units)
Table 83. Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2020-2025) & (USD Million)
Table 84. Asia-Pacific Long-Acting Insulin Analogue Consumption Value by Region (2026-2031) & (USD Million)
Table 85. South America Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 86. South America Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 87. South America Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 88. South America Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 89. South America Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 90. South America Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 91. South America Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 92. South America Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 93. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2020-2025) & (K Units)
Table 94. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Type (2026-2031) & (K Units)
Table 95. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2020-2025) & (K Units)
Table 96. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Application (2026-2031) & (K Units)
Table 97. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2020-2025) & (K Units)
Table 98. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity by Country (2026-2031) & (K Units)
Table 99. Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2020-2025) & (USD Million)
Table 100. Middle East & Africa Long-Acting Insulin Analogue Consumption Value by Country (2026-2031) & (USD Million)
Table 101. Long-Acting Insulin Analogue Raw Material
Table 102. Key Manufacturers of Long-Acting Insulin Analogue Raw Materials
Table 103. Long-Acting Insulin Analogue Typical Distributors
Table 104. Long-Acting Insulin Analogue Typical Customers
LIST OF FIGURES
Figure 1. Long-Acting Insulin Analogue Picture
Figure 2. Global Long-Acting Insulin Analogue Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Long-Acting Insulin Analogue Revenue Market Share by Type in 2024
Figure 4. Insulin Glargine Examples
Figure 5. Insulin Detemir Examples
Figure 6. Insulin Degludec Examples
Figure 7. Global Long-Acting Insulin Analogue Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Global Long-Acting Insulin Analogue Revenue Market Share by Application in 2024
Figure 9. Type 2 Diabetes Examples
Figure 10. Type 1 Diabetes Examples
Figure 11. Gestational Diabetes Examples
Figure 12. Other Diabetes Examples
Figure 13. Global Long-Acting Insulin Analogue Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Long-Acting Insulin Analogue Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Long-Acting Insulin Analogue Sales Quantity (2020-2031) & (K Units)
Figure 16. Global Long-Acting Insulin Analogue Price (2020-2031) & (US$/Unit)
Figure 17. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Manufacturer in 2024
Figure 18. Global Long-Acting Insulin Analogue Revenue Market Share by Manufacturer in 2024
Figure 19. Producer Shipments of Long-Acting Insulin Analogue by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 20. Top 3 Long-Acting Insulin Analogue Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Long-Acting Insulin Analogue Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Region (2020-2031)
Figure 23. Global Long-Acting Insulin Analogue Consumption Value Market Share by Region (2020-2031)
Figure 24. North America Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 25. Europe Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 27. South America Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 29. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 30. Global Long-Acting Insulin Analogue Consumption Value Market Share by Type (2020-2031)
Figure 31. Global Long-Acting Insulin Analogue Average Price by Type (2020-2031) & (US$/Unit)
Figure 32. Global Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 33. Global Long-Acting Insulin Analogue Revenue Market Share by Application (2020-2031)
Figure 34. Global Long-Acting Insulin Analogue Average Price by Application (2020-2031) & (US$/Unit)
Figure 35. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 36. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 37. North America Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 38. North America Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 39. United States Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 40. Canada Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 41. Mexico Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 42. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 43. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 44. Europe Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 45. Europe Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 46. Germany Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 47. France Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 48. United Kingdom Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 49. Russia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 50. Italy Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 52. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Long-Acting Insulin Analogue Sales Quantity Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Long-Acting Insulin Analogue Consumption Value Market Share by Region (2020-2031)
Figure 55. China Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 56. Japan Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 57. South Korea Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 58. India Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 59. Southeast Asia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 60. Australia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 61. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 62. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 63. South America Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 64. South America Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 65. Brazil Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 66. Argentina Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Long-Acting Insulin Analogue Sales Quantity Market Share by Country (2020-2031)
Figure 70. Middle East & Africa Long-Acting Insulin Analogue Consumption Value Market Share by Country (2020-2031)
Figure 71. Turkey Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 72. Egypt Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 74. South Africa Long-Acting Insulin Analogue Consumption Value (2020-2031) & (USD Million)
Figure 75. Long-Acting Insulin Analogue Market Drivers
Figure 76. Long-Acting Insulin Analogue Market Restraints
Figure 77. Long-Acting Insulin Analogue Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Long-Acting Insulin Analogue in 2024
Figure 80. Manufacturing Process Analysis of Long-Acting Insulin Analogue
Figure 81. Long-Acting Insulin Analogue Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
